2- chloro- 3- (1- hydroxy- 5,6,7,8- tetrahydronaphthalen- 2- yl)- 6- oxo- 5- phenyl- 7H- thieno)(2,3- b)pyridin- 4- olate potassium

a thienopyridone small molecule AMPK activator

Also Known As:

PXL-770; PXL770; potassium, 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo-5-phenyl-7H-thieno)(2,3-b)pyridin-4-olate

Networked: 5 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hallakou-Bozec, Sophie: 4 articles (01/2022 - 11/2021)
2.	Moller, David E: 4 articles (01/2022 - 11/2021)
3.	Bolze, Sebastien: 3 articles (01/2022 - 11/2021)
4.	Fouqueray, Pascale: 3 articles (01/2022 - 11/2021)
5.	Gluais-Dagorn, Pascale: 2 articles (01/2022 - 12/2021)
6.	Monternier, Pierre-Axel: 2 articles (01/2022 - 01/2022)
7.	Theurey, Pierre: 2 articles (01/2022 - 12/2021)
8.	Cusi, Kenneth: 2 articles (12/2021 - 11/2021)
9.	Dubourg, Julie: 2 articles (12/2021 - 11/2021)
10.	Grouin, Jean-Marie: 2 articles (12/2021 - 11/2021)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 11/01/2021 - "We aimed to assess efficacy and safety of PXL770, a novel direct AMPK activator, in patients with non-alcoholic fatty liver disease (NAFLD). " 11/01/2021 - "Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study." 11/01/2021 - "Given indications that metabolic features improved with PXL770 treatment, AMPK activation might be a promising pharmacological target for patients with type 2 diabetes and NAFLD, and could also be considered for further assessment in patients with non-alcoholic steatohepatitis. " 12/21/2021 - "In a randomized, double-blind four-week trial, 12 overweight/obese patients with non-alcoholic fatty liver disease (NAFLD) and insulin resistance received PXL770 500 mg QD; 4 subjects received matching placebo. "
2.	Insulin Resistance 12/21/2021 - "PXL770 decreases DNL-both peak and AUC are reduced versus baseline-and improves glycemic parameters and indices of insulin sensitivity versus baseline. " 01/01/2022 - "In rodent models with metabolic syndrome, PXL770 improved glycemia, dyslipidemia, and insulin resistance. " 12/21/2021 - "In a randomized, double-blind four-week trial, 12 overweight/obese patients with non-alcoholic fatty liver disease (NAFLD) and insulin resistance received PXL770 500 mg QD; 4 subjects received matching placebo. "
3.	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/21/2021 - "We aimed to assess pharmacokinetics, safety, and pharmacodynamics of PXL770 in humans with metabolic syndrome-associated fatty liver disease. " 01/01/2022 - "In rodent models with metabolic syndrome, PXL770 improved glycemia, dyslipidemia, and insulin resistance. "
4.	Dyslipidemias (Dyslipidemia) 01/01/2022 - "In rodent models with metabolic syndrome, PXL770 improved glycemia, dyslipidemia, and insulin resistance. "
5.	Alcoholic Fatty Liver 11/01/2021 - "Given indications that metabolic features improved with PXL770 treatment, AMPK activation might be a promising pharmacological target for patients with type 2 diabetes and NAFLD, and could also be considered for further assessment in patients with non-alcoholic steatohepatitis. "

Related Drugs and Biologics

1.	Adenylate Kinase
2.	Urea (Carbamide)
3.	Colforsin
4.	Deamino Arginine Vasopressin (Desmopressin)